Related Experiment Video

Updated: Jan 22, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

[Immunotherapy for patients with malignant melanoma and brain metastases]

Line Thing Simonsen1, Anne Mette Sjørslev Schmidt, Trine Heide Øllegaard

  • 1linethingsimonsen@gmail.com.

Ugeskrift for Laeger
|July 4, 2019
PubMed

Insights

New melanoma treatments, including targeted therapy and checkpoint inhibitors, offer hope for brain metastases. Combination therapies like ipilimumab and nivolumab show promise, especially for asymptomatic patients.

Area of Science:

  • Oncology
  • Neurology
  • Dermatology

Background:

  • Melanoma frequently metastasizes to the brain, a historically challenging clinical scenario.
  • Limited effective treatment options existed for melanoma brain metastases previously.

Purpose of the Study:

  • To review current and emerging treatment strategies for melanoma brain metastases.
  • To highlight recent advancements in systemic therapies for this patient population.

Main Methods:

  • Review of recent clinical studies and phase II trials focusing on melanoma brain metastases.
  • Analysis of treatment outcomes for targeted therapies and immune checkpoint inhibitors.

Main Results:

  • Targeted therapy (dabrafenib and trametinib) and checkpoint inhibitors (ipilimumab and nivolumab) have shown promising results.
  • Combination ipilimumab and nivolumab appears most effective for asymptomatic brain metastases based on phase II data.

Conclusions:

  • The landscape of melanoma brain metastases treatment has significantly improved with new systemic therapies.
  • Further investigation is ongoing for the optimal management of symptomatic melanoma brain metastases.

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
2.9K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
235
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
269
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
198